Acne vulgaris currently exhibits a growing pipeline with approximately 49 drug candidates. Acne vulgaris epidemiology analysis forecasts an increase in the total number of prevalent cases in population aged between 10 to 45 years in the 7MM, from 166 million cases in 2016 to 178 million cases in 2023.
Positive Clinical Results Supporting the Pipeline Growth
Various drug candidates have shown positive clinical results and are proceeding towards further development. For instance, In May 2017, Foamix Ltd. announced that FMX101 was generally safe and well tolerated with no drug-related serious adverse events from two double-blind, randomized, placebo-controlled Phase III trials for the treatment of moderate-to-severe acne vulgaris. AndroScience Corporation announced that ASC-J9 in a cream formulation demonstrated a therapeutic effect in lowering lesion counts in moderate to severe acne.
Access Detailed Information on “Acne Vulgaris Therapeutics - Pipeline Analysis, Clinical Trials & Results, Patents, Designations, Collaborations, Patient Size, Epidemiology Forecast to 2023, and Unmet Needs within the Market” at: https://www.psmarketresearch.com/market-analysis/acne-vulgaris-therapeutics-pipeline-analysis
Acne Vulgaris Therapeutics Pipeline has moved towards the development of biologicals and peptides
According to the research findings, the drug candidates in acne vulgaris pipeline have move from small molecule towards biologics and peptides. Allergan plc is in the process of manufacturing ANT-1207, also known as botulinum toxin A topical, under the Phase II stage of development for the treatment of acne vulgaris. The therapeutic candidate is an anticholinergic agent, being developed to be administered by topical route. Helix Biomedix, Inc. in a process of developing peptide-based molecule, which is in the unknown stage for the treatment of acne vulgaris.
Various Technologies for Targeted Drug Delivery Driving the Growth of the Pipeline
Most of the companies possess advanced technologies for the development of acne vulgaris. For instance, Sol-Gel Technologies Ltd. introduced a technology known as “sol-gel”.
Some of the key players developing drugs for the treatment of acne vulgaris therapeutics pipeline include Sol-Gel Technologies Ltd., Realm Therapeutics, Inc., Sienna Biopharmaceuticals, Inc., and Promius Pharma, LLC (subsidiary of Dr. Reddy’s Laboratories Ltd.).
Increasing Prevalence of the disease in the Population Aged 10 to 45 years
Epidemiological analysis of acne vulgaris, forecasts an increase in the total number of prevalent cases of acne vulgaris in the U.S., France, Germany, Spain, and the U.K. Change in the number of prevalent cases of acne vulgaris is associated with change in the population demographics in the population aged between 10 to 45 years in the respective markets. According to the Global Burden of Disease (GBD) study in the U.S., acne vulgaris affects almost 85% of young adults aged 12–25 years. Rising incidence of acne vulgaris in adolescent have been observed due to various factors such as adolescent, puberty, genetics, race, nationality, socioeconomic status, diet, Western diet, dairy, whey protein, chocolate, glycemic index, drugs, smoking, nicotine, and oral contraceptives.
The Research Report, includes:
Epidemiology and Patient Population Forecast to 2023 for 7MM: